Home
OncoSec

OncoSec Market Share Analysis for November 2025

Health > Health Conditions and Concerns

Domainoncosec.com

Year Founded2011

Employees51 - 200

Annual Revenue$25M - $50M

OncoSec

OncoSec (including company regionals)

oncosec.com

See more website traffic and engagement information

OncoSec Revenue up to November 2025 is 25M - 50M

revenue generated by OncoSec top domains

OncoSec top domains revenue over 3 years

Revenue for OncoSec top domains

oncosec.com25M - 50M

See more with Sales Intelligence

Total visits to OncoSec's top domains

Understand OncoSec market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

oncosec.com26

See more with Sales Intelligence

Avg. visit duration in OncoSec's top domains

Analyze OncoSec engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on OncoSec's top domains

See how OncoSec keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

oncosec.com1.02

See more with Sales Intelligence

OncoSec top competitors by domain

Top similar sites in November 2025, ranked by their affinity

cancer.govCompany NameNCI Cancer HospitalEmployees1001 - 5000HQUnited States, Maryland, BethesdaAnnual revenue> $1BTotal visits3.3MHealth > Health Conditions and Concerns

Top technologies used by OncoSec

These are the website technologies, by industry, used by OncoSec top domains

Advertising (6)

DoubleClick

Widget (4)

Twemoji

Social (3)

Google+ Platform

Audio Video Media (2)

YouTube

More Technologies

11

See all

News & Signals from OncoSec

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsNew Jersey Economic Development Association invested into OncoSec Medical Incorporated $3.49M on Apr 27th '23.OncoSec Medical Incorporated (NASDAQ: ONCS ) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to target cancer cells and eradicate disease, today announced the receipt of $3.49 million in tax credit certificates from the New Jersey Economic Development Authority (NJEDA).

NewsOncoSec Medical Incorporated launched KEYNOTE-890 on Jan 1st '18.In 2018, OncoSec launched a Phase II clinical trial called KEYNOTE-890, which assessed TAVO-EP in combination with Merck’s blockbuster anti-PD-1 drug Keytruda for the treatment of late-stage and triple-negative breast cancer.